TCL1Aの異常な活性化により,クローナル血液形成における幹細胞の拡張が促進される
Joshua S Weinstock1, Jayakrishnan Gopakumar2, Bala Bharathi Burugula3
1Center for Statistical Genetics, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA.
Nature
|April 12, 2023
まとめ
がんに関連した血液幹細胞のクローンの成長を遅らせます. この保護効果はTCL1Aという 細胞の膨張を誘発する遺伝子が媒介しています
科学分野:
- 血液学
- 遺伝学
- 癌 生物学
背景:
- 駆動遺伝子の変異は,血液形成幹細胞 (HSC) に適性優位性を与え,クローナル血液形成と血液がんのリスク増加につながります.
- この適性優位性の背後にあるメカニズムは,クローン膨張率に関する限られたデータのために,十分に理解されていません.
- クローナル血液形成は,様々な血液学的悪性腫瘍の重要な前駆体である.
研究 の 目的:
- クローン造血における体格優位性の遺伝的根拠を調査する.
- ドライバ変異を持つHSCの拡大率に影響を与える要因を特定する.
- クロナル血液形成の病原性におけるTCL1Aの役割を解明する.
主な方法:
- 単一の時間点データからクローン膨張率を推論するための新しい方法の開発.
- この方法をクローナル血液形成の5,071人のコホートに適用する.
- 拡張率との遺伝的関連を特定するための全ゲノム関連研究 (GWAS) in vitroおよびin vivo機能分析
主要な成果:
- TCL1Aプロモーターにおける一般的なポリモルフィズムは,特にTET2,ASXL1,SF3B1,SRSF2の変異では,クローンの拡張が遅かったが,DNMT3Aはそうではなかった.
- TET2またはASXL1変異によってTCL1A発現が誘発され,HSCの拡大をインビトロで促進した.
- 保護性アレルはTCL1Aの発現とHSCの膨張を減少させ,強制的なTCL1Aの発現は,in vitroとin vivoでHSCの膨張を促進した.
結論:
- 複製性血液形成におけるいくつかの一般的な誘導因子変異によってもたらされるフィットネス上の優位性は,TCL1Aの活性化によって媒介され得る.
- TCL1Aは,HSCの拡張を促進し,クローナル血液形成に寄与する上で重要な役割を果たします.
- TCL1Aの遺伝的変異は,クローナル血液形成のリスクと進行を調節することができます.
関連する概念動画
T Cell Activation and Clonal Selection
939
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
939
Regulation of Hematopoietic Stem Cells
3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Multipotency of Hematopoietic Stem Cells
3.2K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.2K
Lineage Commitment
3.0K
Commitment is the process whereby stem cells:
3.0K
Stem Cell Therapy for Tissue Regeneration
4.1K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.1K
Cancer Stem Cells and Tumor Maintenance
5.0K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K


